Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND IBUPROFEN versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND IBUPROFEN versus MECLOFENAMATE SODIUM.
HYDROCODONE BITARTRATE AND IBUPROFEN vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a semisynthetic opioid agonist with selectivity for mu-opioid receptors, producing analgesia and sedation. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby providing anti-inflammatory, analgesic, and antipyretic effects.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
One tablet (hydrocodone bitartrate 5 mg/ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
Hydrocodone: 3.8-4.5 hours (immediate release); Ibuprofen: 1.8-2.5 hours (racemic, S-enantiomer slightly shorter). Clinical context: dosing every 4-6 hours due to hydrocodone half-life.
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Hydrocodone: primarily renal (60-70% as metabolites, <12% unchanged); Ibuprofen: primarily renal (90% as metabolites and conjugates, <1% unchanged), minor biliary/fecal.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category D/X
Category C
NSAID
NSAID